《 bioRxiv,4月14日,Identification of potential vaccine candidates against SARS-CoV-2, A step forward to fight novel coronavirus 2019-nCoV: A Reverse Vaccinology Approach》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-04-15
  • Identification of potential vaccine candidates against SARS-CoV-2, A step forward to fight novel coronavirus 2019-nCoV: A Reverse Vaccinology Approach

    View ORCID ProfileEkta Gupta, View ORCID ProfileRupesh Kumar Mishra, View ORCID ProfileRavi Ranjan Kumar Niraj

    doi: https://doi.org/10.1101/2020.04.13.039198

    Abstract

    The recent Coronavirus Disease 2019 (COVID-19) causes an immense health crisis to global public health. The World Health Organization (WHO) declared the COVID-19 as a pandemic. The COVID-19 is the etiologic agent of a recently arose disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Presently, there is no vaccine available against this emerged viral disease. Therefore, it is indeed a need of the hour to develop an effectual and safe vaccine against this decidedly pandemic disease. In the current study, we collected SARS-CoV-2 genome from Indian geographical origin against human host, further more using reverse vaccinology and immunoinformatics tools here we claim effective vaccine candidates that can be mile stone in battle against COVID19. This novel study divulged two promising antigenic peptide GVYFASTEK and NFRVQPTESIV from surface glycoproteins (protein accession no. - QIA98583.1 and QHS34546.1) of SARS-CoV-2, which were predicated to be interacted with class I and class II MHC alleles and showed up to 90% conservancy and high value of antigenicity. Subsequently, the molecular docking studies were verified molecular interaction of these prime antigenic peptides with the residues of HLA-A*11-01 allele for MHC Class I and HLA DRB1*04-01 allele for MHC class II. After vigorous analysis, these peptides were predicted to be suitable epitopes which are capable to elicit the strong cell-mediated immune response against the SARS-CoV-2. Consequences from the present study could facilitate selecting SARS-CoV-2 epitopes for vaccine production pipelines in the immediate future. This novel research will certainly pave the way for a fast, reliable and virtuous platform to provide timely countermeasure of this dangerous pandemic disease, COVID-19. Keywords: COVID-19, SARS-CoV-2, Immunoinformatics, Reverse vaccinology, Molecular docking, Epitope, Vaccine candidates.

    *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.

  • 原文来源:https://www.biorxiv.org/content/10.1101/2020.04.13.039198v1
相关报告
  • 《BioRxiv,2月4日,Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-05
    • Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies Syed Faraz Ahmed, Ahmed A. Quadeer, Matthew R. McKay doi: https://doi.org/10.1101/2020.02.03.933226 Abstract The beginning of 2020 has seen the emergence of the 2019 novel coronavirus (2019-nCoV) outbreak. Since the first reported case in the Wuhan city of China, 2019-nCoV has spread to other cities in China as well as to multiple countries across four continents. There is an imminent need to better understand this novel virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against 2019-nCoV by considering the high genetic similarity between 2019-nCoV and the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to 2019-nCoV proteins. As no mutation has been observed in these identified epitopes among the available 2019-nCoV sequences (as of 29 January 2020), immune targeting of these epitopes may potentially offer protection against 2019-nCoV. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against 2019-nCoV. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.
  • 《4月14日_利用反向疫苗学方法,识别针对SARS-CoV-2的潜在候选疫苗》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-16
    • 1.时间:2020年4月14日 2.机构或团队:Dr. B. Lal生物技术研究所、印度阿米提大学 3.事件概要: Dr. B. Lal生物技术研究所和印度阿米提大学的科研人员在bioRxiv预印本平台发表题为“Identification of potential vaccine candidates against SARS-CoV-2, A step forward to fight novel coronavirus 2019-nCoV: A Reverse Vaccinology Approach”的文章。 文章指出,研究人员从印度的地理起源中收集了针对人类宿主的SARS-CoV-2基因组,进一步使用反向疫苗学和免疫信息学工具,发现了可以对抗COVID-19的有效候选疫苗。该研究从SARS-CoV-2的表面糖蛋白(蛋白保藏号为QIA98583.1和QHS34546.1)中发现了两个很有前途的抗原肽GVYFASTEK和NFRVQPTESIV,它们被认为与I类和II类MHC等位基因相互作用,显示出高达90%的保守性和高抗原值。随后,分子对接研究验证了这些主要抗原肽与MHC I类的HLA-A*11-01等位基因和MHC II类的HLA DRB1*04-01等位基因残基的分子相互作用。经分析,这些肽被预测为合适的表位,能够引发针对SARS-CoV-2的强烈细胞介导的免疫反应。研究结果可能有助于在不久的将来为疫苗生产选择SARS-CoV-2表位。文章称,其研究将为建立一个快速、可靠和良好的平台铺平道路,以便为对抗COVID-19提供及时的对策。 *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用。 4.附件: 原文链接:https://www.biorxiv.org/content/10.1101/2020.04.13.039198v1